+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Drugs for Spinal Muscular Atrophy Market by Product Type (Antisense Oligonucleotide, Gene Therapy, Small Molecule), Treatment Type (Combination Therapy, Monotherapy), Distribution Channel, Patient Age Group - Global Forecast 2025-2030- Product Image
Drugs for Spinal Muscular Atrophy Market by Product Type (Antisense Oligonucleotide, Gene Therapy, Small Molecule), Treatment Type (Combination Therapy, Monotherapy), Distribution Channel, Patient Age Group - Global Forecast 2025-2030- Product Image
Sale

Drugs for Spinal Muscular Atrophy Market by Product Type (Antisense Oligonucleotide, Gene Therapy, Small Molecule), Treatment Type (Combination Therapy, Monotherapy), Distribution Channel, Patient Age Group - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 195 Pages
  • August 2025
  • Region: Global
  • 360iResearch™
  • ID: 6078786
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The spinal muscular atrophy (SMA) market is entering a pivotal period marked by the rapid evolution of disease-modifying therapies and a transformation in patient care approaches. Senior decision-makers face a landscape shaped by breakthrough innovations, shifting regulatory environments, and new economic pressures—as well as a growing focus on tailored solutions for diverse patient groups.

Market Snapshot: Spinal Muscular Atrophy Therapeutics

The global SMA therapeutics market is experiencing significant momentum, with an expanding array of advanced treatments and competitive activity driving strategic realignments. Heightened collaboration among pharmaceutical leaders, academic institutions, and advocacy organizations continues to redefine product development strategies and adoption rates. Newborn screening expansion, regulatory acceleration, and the introduction of novel delivery platforms underscore the urgency for informed decision-making at both operational and executive levels.

Scope & Segmentation

This report delivers an in-depth analysis of the evolving spinal muscular atrophy market, with structured categorization across critical dimensions:

  • Product Type: Antisense oligonucleotide (notably Nusinersen), gene therapy (Onasemnogene Abeparvovec), small molecule (Risdiplam)
  • Treatment Type: Combination therapy, monotherapy
  • Distribution Channel: Home healthcare, hospital pharmacy, specialty clinic
  • Patient Age Group: Adult, child and adolescent, infant and toddler
  • Geographic Coverage: Americas (including United States, Canada, Mexico, Brazil, Argentina), Europe, Middle East & Africa (covering United Kingdom, Germany, France, multiple other markets), Asia-Pacific (including China, India, Japan, Australia, and Southeast Asia)
  • Company Coverage: Astellas Pharma Inc., Biogen Inc., Novartis AG, PTC Therapeutics, Inc., F. Hoffmann-La Roche Ltd.

Technological advances such as gene replacement, antisense oligonucleotides, and small molecule modulators are evaluated, highlighting their respective roles in shaping patient outcomes and pipeline strategies.

Key Takeaways: Navigating the SMA Therapeutics Landscape

  • Recent clinical breakthroughs have shifted SMA from a fatal pediatric disorder to a condition with multiple long-term management options involving gene therapies and RNA-modifying treatments.
  • Accelerated regulatory approvals and adaptive trial models now facilitate faster patient access, though they require ongoing post-market evidence and cross-stakeholder collaboration.
  • Segmentation by product, delivery route, and patient age informs commercialization strategies, with newborn screening driving early interventions and age-tailored treatment approaches maximizing outcomes.
  • Personalized medicine and the integration of digital remote monitoring increase emphasis on precision delivery and biomarker-driven development, further diversifying competitive strategies.
  • Strategic partnerships—encompassing industry, academia, and patient advocacy—are crucial for real-world data generation, regulatory negotiation, and broadening patient access.

Tariff Impact on SMA Therapeutics Supply Chains

The newly implemented 2025 United States tariffs on imported active pharmaceutical ingredients and viral vectors have introduced cost pressures throughout the SMA supply chain. As a result, manufacturers are reassessing global sourcing strategies, increasingly turning to domestic contract development and manufacturing partners. These shifts impact stakeholder pricing negotiations, supply resilience, and the allocation of clinical trial resources, while encouraging supply chain vertical integration to safeguard access to essential therapies.

Spinal Muscular Atrophy Market Methodology & Data Sources

Our research integrates an exhaustive review of peer-reviewed literature, clinical stewardship records, global regulatory guidelines, and treatment outcomes databases. Expert insights were collected via structured interviews with leading neurologists, pharmacoeconomists, health technology assessors, and patient advocacy representatives. Results were validated through cross-source triangulation and expert peer review, ensuring analytic rigor and multidimensional perspectives on SMA treatment trends.

Primary Keyword: Spinal Muscular Atrophy

Spinal muscular atrophy research is advancing rapidly, with gene therapies, antisense oligonucleotides, and novel small molecule treatments redefining disease management standards. Comprehensive patient and channel segmentation, coupled with regulatory innovation, fosters a more responsive market environment and highlights the need for adaptive supply strategies following new tariffs.

Why This Report Matters

  • Supports evidence-based decisions regarding investment, R&D prioritization, and market entry—essential in a dynamic and highly regulated disease space.
  • Helps stakeholders identify partnership opportunities, optimize commercialization strategies, and stay ahead of tariff-related supply challenges.

Conclusion

The SMA therapeutics market is rapidly transforming through scientific, regulatory, and economic shifts. Decision-makers who adopt data-driven strategies and prioritize cross-sector collaboration will be best positioned to secure patient access and achieve sustainable growth.



This product will be delivered within 1-3 business days.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Rapid adoption of next-generation gene therapies reshaping SMA treatment protocols and patient outcomes
5.2. Expansion of national newborn screening initiatives enabling earlier SMA diagnosis and therapeutic intervention
5.3. Advancements in antisense oligonucleotide therapies improving efficacy and dosing convenience for SMA patients
5.4. Integration of telemedicine and digital health tools enhancing remote monitoring and management of SMA disease progression
5.5. Strategic collaborations between biotech companies and academic centers accelerating novel SMA drug discovery and development
5.6. Emergence of long-term real-world evidence studies assessing safety and effectiveness of SMA treatments across demographics
5.7. Increasing competition from biosimilars and generics driving cost-containment and pricing pressures in the SMA therapeutics market
5.8. Investment in innovative intrathecal delivery systems optimizing targeted gene therapy administration for SMA patients
5.9. Regulatory alignment efforts across major markets streamlining global approval pathways for groundbreaking SMA therapies
5.10. Patient advocacy groups influencing clinical trial designs and access policies to improve SMA treatment availability worldwide
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Drugs for Spinal Muscular Atrophy Market, by Product Type
8.1. Introduction
8.2. Antisense Oligonucleotide
8.2.1. Nusinersen
8.3. Gene Therapy
8.3.1. Onasemnogene Abeparvovec
8.4. Small Molecule
8.4.1. Risdiplam
9. Drugs for Spinal Muscular Atrophy Market, by Treatment Type
9.1. Introduction
9.2. Combination Therapy
9.3. Monotherapy
10. Drugs for Spinal Muscular Atrophy Market, by Distribution Channel
10.1. Introduction
10.2. Home Healthcare
10.3. Hospital Pharmacy
10.4. Specialty Clinic
11. Drugs for Spinal Muscular Atrophy Market, by Patient Age Group
11.1. Introduction
11.2. Adult
11.3. Child And Adolescent
11.4. Infant And Toddler
12. Americas Drugs for Spinal Muscular Atrophy Market
12.1. Introduction
12.2. United States
12.3. Canada
12.4. Mexico
12.5. Brazil
12.6. Argentina
13. Europe, Middle East & Africa Drugs for Spinal Muscular Atrophy Market
13.1. Introduction
13.2. United Kingdom
13.3. Germany
13.4. France
13.5. Russia
13.6. Italy
13.7. Spain
13.8. United Arab Emirates
13.9. Saudi Arabia
13.10. South Africa
13.11. Denmark
13.12. Netherlands
13.13. Qatar
13.14. Finland
13.15. Sweden
13.16. Nigeria
13.17. Egypt
13.18. Turkey
13.19. Israel
13.20. Norway
13.21. Poland
13.22. Switzerland
14. Asia-Pacific Drugs for Spinal Muscular Atrophy Market
14.1. Introduction
14.2. China
14.3. India
14.4. Japan
14.5. Australia
14.6. South Korea
14.7. Indonesia
14.8. Thailand
14.9. Philippines
14.10. Malaysia
14.11. Singapore
14.12. Vietnam
14.13. Taiwan
15. Competitive Landscape
15.1. Market Share Analysis, 2024
15.2. FPNV Positioning Matrix, 2024
15.3. Competitive Analysis
15.3.1. Astellas Pharma Inc.
15.3.2. Biogen Inc.
15.3.3. Novartis AG
15.3.4. PTC Therapeutics, Inc.
15.3.5. F. Hoffmann-La Roche Ltd.
16. ResearchAI
17. ResearchStatistics
18. ResearchContacts
19. ResearchArticles
20. Appendix
List of Figures
FIGURE 1. DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2030 (%)
FIGURE 6. GLOBAL DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 10. GLOBAL DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY PATIENT AGE GROUP, 2024 VS 2030 (%)
FIGURE 12. GLOBAL DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY PATIENT AGE GROUP, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. AMERICAS DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 14. AMERICAS DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. UNITED STATES DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 16. UNITED STATES DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. EUROPE, MIDDLE EAST & AFRICA DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. EUROPE, MIDDLE EAST & AFRICA DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. ASIA-PACIFIC DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. ASIA-PACIFIC DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 22. DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 23. DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET: RESEARCHAI
FIGURE 24. DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET: RESEARCHSTATISTICS
FIGURE 25. DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET: RESEARCHCONTACTS
FIGURE 26. DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY ANTISENSE OLIGONUCLEOTIDE, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY ANTISENSE OLIGONUCLEOTIDE, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY NUSINERSEN, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY NUSINERSEN, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY ANTISENSE OLIGONUCLEOTIDE, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY ANTISENSE OLIGONUCLEOTIDE, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY GENE THERAPY, BY REGION, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY GENE THERAPY, BY REGION, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY ONASEMNOGENE ABEPARVOVEC, BY REGION, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY ONASEMNOGENE ABEPARVOVEC, BY REGION, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY GENE THERAPY, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY GENE THERAPY, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY SMALL MOLECULE, BY REGION, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY SMALL MOLECULE, BY REGION, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY RISDIPLAM, BY REGION, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY RISDIPLAM, BY REGION, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY SMALL MOLECULE, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY SMALL MOLECULE, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY COMBINATION THERAPY, BY REGION, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY COMBINATION THERAPY, BY REGION, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY MONOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY MONOTHERAPY, BY REGION, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY HOME HEALTHCARE, BY REGION, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY HOME HEALTHCARE, BY REGION, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY SPECIALTY CLINIC, BY REGION, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY SPECIALTY CLINIC, BY REGION, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 45. GLOBAL DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY ADULT, BY REGION, 2018-2024 (USD MILLION)
TABLE 46. GLOBAL DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY ADULT, BY REGION, 2025-2030 (USD MILLION)
TABLE 47. GLOBAL DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY CHILD AND ADOLESCENT, BY REGION, 2018-2024 (USD MILLION)
TABLE 48. GLOBAL DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY CHILD AND ADOLESCENT, BY REGION, 2025-2030 (USD MILLION)
TABLE 49. GLOBAL DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY INFANT AND TODDLER, BY REGION, 2018-2024 (USD MILLION)
TABLE 50. GLOBAL DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY INFANT AND TODDLER, BY REGION, 2025-2030 (USD MILLION)
TABLE 51. AMERICAS DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 52. AMERICAS DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 53. AMERICAS DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY ANTISENSE OLIGONUCLEOTIDE, 2018-2024 (USD MILLION)
TABLE 54. AMERICAS DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY ANTISENSE OLIGONUCLEOTIDE, 2025-2030 (USD MILLION)
TABLE 55. AMERICAS DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY GENE THERAPY, 2018-2024 (USD MILLION)
TABLE 56. AMERICAS DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY GENE THERAPY, 2025-2030 (USD MILLION)
TABLE 57. AMERICAS DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY SMALL MOLECULE, 2018-2024 (USD MILLION)
TABLE 58. AMERICAS DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY SMALL MOLECULE, 2025-2030 (USD MILLION)
TABLE 59. AMERICAS DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 60. AMERICAS DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 61. AMERICAS DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 62. AMERICAS DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 63. AMERICAS DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 64. AMERICAS DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 65. AMERICAS DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 66. AMERICAS DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 67. UNITED STATES DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 68. UNITED STATES DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 69. UNITED STATES DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY ANTISENSE OLIGONUCLEOTIDE, 2018-2024 (USD MILLION)
TABLE 70. UNITED STATES DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY ANTISENSE OLIGONUCLEOTIDE, 2025-2030 (USD MILLION)
TABLE 71. UNITED STATES DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY GENE THERAPY, 2018-2024 (USD MILLION)
TABLE 72. UNITED STATES DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY GENE THERAPY, 2025-2030 (USD MILLION)
TABLE 73. UNITED STATES DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY SMALL MOLECULE, 2018-2024 (USD MILLION)
TABLE 74. UNITED STATES DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY SMALL MOLECULE, 2025-2030 (USD MILLION)
TABLE 75. UNITED STATES DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 76. UNITED STATES DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 77. UNITED STATES DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 78. UNITED STATES DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 79. UNITED STATES DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 80. UNITED STATES DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 81. UNITED STATES DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 82. UNITED STATES DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 83. CANADA DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 84. CANADA DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 85. CANADA DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY ANTISENSE OLIGONUCLEOTIDE, 2018-2024 (USD MILLION)
TABLE 86. CANADA DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY ANTISENSE OLIGONUCLEOTIDE, 2025-2030 (USD MILLION)
TABLE 87. CANADA DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY GENE THERAPY, 2018-2024 (USD MILLION)
TABLE 88. CANADA DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY GENE THERAPY, 2025-2030 (USD MILLION)
TABLE 89. CANADA DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY SMALL MOLECULE, 2018-2024 (USD MILLION)
TABLE 90. CANADA DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY SMALL MOLECULE, 2025-2030 (USD MILLION)
TABLE 91. CANADA DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 92. CANADA DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 93. CANADA DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 94. CANADA DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 95. CANADA DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 96. CANADA DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 97. MEXICO DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 98. MEXICO DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 99. MEXICO DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY ANTISENSE OLIGONUCLEOTIDE, 2018-2024 (USD MILLION)
TABLE 100. MEXICO DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY ANTISENSE OLIGONUCLEOTIDE, 2025-2030 (USD MILLION)
TABLE 101. MEXICO DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY GENE THERAPY, 2018-2024 (USD MILLION)
TABLE 102. MEXICO DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY GENE THERAPY, 2025-2030 (USD MILLION)
TABLE 103. MEXICO DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY SMALL MOLECULE, 2018-2024 (USD MILLION)
TABLE 104. MEXICO DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY SMALL MOLECULE, 2025-2030 (USD MILLION)
TABLE 105. MEXICO DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 106. MEXICO DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 107. MEXICO DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 108. MEXICO DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 109. MEXICO DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 110. MEXICO DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 111. BRAZIL DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 112. BRAZIL DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 113. BRAZIL DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY ANTISENSE OLIGONUCLEOTIDE, 2018-2024 (USD MILLION)
TABLE 114. BRAZIL DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY ANTISENSE OLIGONUCLEOTIDE, 2025-2030 (USD MILLION)
TABLE 115. BRAZIL DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY GENE THERAPY, 2018-2024 (USD MILLION)
TABLE 116. BRAZIL DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY GENE THERAPY, 2025-2030 (USD MILLION)
TABLE 117. BRAZIL DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY SMALL MOLECULE, 2018-2024 (USD MILLION)
TABLE 118. BRAZIL DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY SMALL MOLECULE, 2025-2030 (USD MILLION)
TABLE 119. BRAZIL DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 120. BRAZIL DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 121. BRAZIL DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 122. BRAZIL DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 123. BRAZIL DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 124. BRAZIL DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 125. ARGENTINA DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 126. ARGENTINA DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 127. ARGENTINA DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY ANTISENSE OLIGONUCLEOTIDE, 2018-2024 (USD MILLION)
TABLE 128. ARGENTINA DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY ANTISENSE OLIGONUCLEOTIDE, 2025-2030 (USD MILLION)
TABLE 129. ARGENTINA DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY GENE THERAPY, 2018-2024 (USD MILLION)
TABLE 130. ARGENTINA DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY GENE THERAPY, 2025-2030 (USD MILLION)
TABLE 131. ARGENTINA DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY SMALL MOLECULE, 2018-2024 (USD MILLION)
TABLE 132. ARGENTINA DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY SMALL MOLECULE, 2025-2030 (USD MILLION)
TABLE 133. ARGENTINA DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 134. ARGENTINA DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 135. ARGENTINA DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 136. ARGENTINA DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 137. ARGENTINA DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 138. ARGENTINA DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 139. EUROPE, MIDDLE EAST & AFRICA DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 140. EUROPE, MIDDLE EAST & AFRICA DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 141. EUROPE, MIDDLE EAST & AFRICA DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY ANTISENSE OLIGONUCLEOTIDE, 2018-2024 (USD MILLION)
TABLE 142. EUROPE, MIDDLE EAST & AFRICA DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY ANTISENSE OLIGONUCLEOTIDE, 2025-2030 (USD MILLION)
TABLE 143. EUROPE, MIDDLE EAST & AFRICA DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY GENE THERAPY, 2018-2024 (USD MILLION)
TABLE 144. EUROPE, MIDDLE EAST & AFRICA DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY GENE THERAPY, 2025-2030 (USD MILLION)
TABLE 145. EUROPE, MIDDLE EAST & AFRICA DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY SMALL MOLECULE, 2018-2024 (USD MILLION)
TABLE 146. EUROPE, MIDDLE EAST & AFRICA DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY SMALL MOLECULE, 2025-2030 (USD MILLION)
TABLE 147. EUROPE, MIDDLE EAST & AFRICA DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 148. EUROPE, MIDDLE EAST & AFRICA DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 149. EUROPE, MIDDLE EAST & AFRICA DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 150. EUROPE, MIDDLE EAST & AFRICA DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 151. EUROPE, MIDDLE EAST & AFRICA DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 152. EUROPE, MIDDLE EAST & AFRICA DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 153. EUROPE, MIDDLE EAST & AFRICA DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 154. EUROPE, MIDDLE EAST & AFRICA DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 155. UNITED KINGDOM DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 156. UNITED KINGDOM DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 157. UNITED KINGDOM DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY ANTISENSE OLIGONUCLEOTIDE, 2018-2024 (USD MILLION)
TABLE 158. UNITED KINGDOM DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY ANTISENSE OLIGONUCLEOTIDE, 2025-2030 (USD MILLION)
TABLE 159. UNITED KINGDOM DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY GENE THERAPY, 2018-2024 (USD MILLION)
TABLE 160. UNITED KINGDOM DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY GENE THERAPY, 2025-2030 (USD MILLION)
TABLE 161. UNITED KINGDOM DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY SMALL MOLECULE, 2018-2024 (USD MILLION)
TABLE 162. UNITED KINGDOM DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY SMALL MOLECULE, 2025-2030 (USD MILLION)
TABLE 163. UNITED KINGDOM DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 164. UNITED KINGDOM DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 165. UNITED KINGDOM DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 166. UNITED KINGDOM DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 167. UNITED KINGDOM DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 168. UNITED KINGDOM DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 169. GERMANY DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 170. GERMANY DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 171. GERMANY DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY ANTISENSE OLIGONUCLEOTIDE, 2018-2024 (USD MILLION)
TABLE 172. GERMANY DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY ANTISENSE OLIGONUCLEOTIDE, 2025-2030 (USD MILLION)
TABLE 173. GERMANY DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY GENE THERAPY, 2018-2024 (USD MILLION)
TABLE 174. GERMANY DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY GENE THERAPY, 2025-2030 (USD MILLION)
TABLE 175. GERMANY DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY SMALL MOLECULE, 2018-2024 (USD MILLION)
TABLE 176. GERMANY DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY SMALL MOLECULE, 2025-2030 (USD MILLION)
TABLE 177. GERMANY DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 178. GERMANY DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 179. GERMANY DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 180. GERMANY DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 181. GERMANY DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 182. GERMANY DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 183. FRANCE DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 184. FRANCE DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 185. FRANCE DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY ANTISENSE OLIGONUCLEOTIDE, 2018-2024 (USD MILLION)
TABLE 186. FRANCE DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY ANTISENSE OLIGONUCLEOTIDE, 2025-2030 (USD MILLION)
TABLE 187. FRANCE DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY GENE THERAPY, 2018-2024 (USD MILLION)
TABLE 188. FRANCE DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY GENE THERAPY, 2025-2030 (USD MILLION)
TABLE 189. FRANCE DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY SMALL MOLECULE, 2018-2024 (USD MILLION)
TABLE 190. FRANCE DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY SMALL MOLECULE, 2025-2030 (USD MILLION)
TABLE 191. FRANCE DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 192. FRANCE DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 193. FRANCE DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 194. FRANCE DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 195. FRANCE DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 196. FRANCE DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 197. RUSSIA DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 198. RUSSIA DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 199. RUSSIA DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY ANTISENSE OLIGONUCLEOTIDE, 2018-2024 (USD MILLION)
TABLE 200. RUSSIA DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY ANTISENSE OLIGONUCLEOTIDE, 2025-2030 (USD MILLION)
TABLE 201. RUSSIA DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY GENE THERAPY, 2018-2024 (USD MILLION)
TABLE 202. RUSSIA DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY GENE THERAPY, 2025-2030 (USD MILLION)
TABLE 203. RUSSIA DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY SMALL MOLECULE, 2018-2024 (USD MILLION)
TABLE 204. RUSSIA DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY SMALL MOLECULE, 2025-2030 (USD MILLION)
TABLE 205. RUSSIA DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 206. RUSSIA DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 207. RUSSIA DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 208. RUSSIA DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 209. RUSSIA DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 210. RUSSIA DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 211. ITALY DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 212. ITALY DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 213. ITALY DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY ANTISENSE OLIGONUCLEOTIDE, 2018-2024 (USD MILLION)
TABLE 214. ITALY DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY ANTISENSE OLIGONUCLEOTIDE, 2025-2030 (USD MILLION)
TABLE 215. ITALY DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY GENE THERAPY, 2018-2024 (USD MILLION)
TABLE 216. ITALY DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY GENE THERAPY, 2025-2030 (USD MILLION)
TABLE 217. ITALY DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY SMALL MOLECULE, 2018-2024 (USD MILLION)
TABLE 218. ITALY DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY SMALL MOLECULE, 2025-2030 (USD MILLION)
TABLE 219. ITALY DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 220. ITALY DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 221. ITALY DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 222. ITALY DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 223. ITALY DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 224. ITALY DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 225. SPAIN DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 226. SPAIN DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 227. SPAIN DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY ANTISENSE OLIGONUCLEOTIDE, 2018-2024 (USD MILLION)
TABLE 228. SPAIN DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY ANTISENSE OLIGONUCLEOTIDE, 2025-2030 (USD MILLION)
TABLE 229. SPAIN DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY GENE THERAPY, 2018-2024 (USD MILLION)
TABLE 230. SPAIN DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY GENE THERAPY, 2025-2030 (USD MILLION)
TABLE 231. SPAIN DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY SMALL MOLECULE, 2018-2024 (USD MILLION)
TABLE 232. SPAIN DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY SMALL MOLECULE, 2025-2030 (USD MILLION)
TABLE 233. SPAIN DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 234. SPAIN DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 235. SPAIN DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 236. SPAIN DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 237. SPAIN DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 238. SPAIN DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 239. UNITED ARAB EMIRATES DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 240. UNITED ARAB EMIRATES DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 241. UNITED ARAB EMIRATES DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY ANTISENSE OLIGONUCLEOTIDE, 2018-2024 (USD MILLION)
TABLE 242. UNITED ARAB EMIRATES DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY ANTISENSE OLIGONUCLEOTIDE, 2025-2030 (USD MILLION)
TABLE 243. UNITED ARAB EMIRATES DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY GENE THERAPY, 2018-2024 (USD MILLION)
TABLE 244. UNITED ARAB EMIRATES DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY GENE THERAPY, 2025-2030 (USD MILLION)
TABLE 245. UNITED ARAB EMIRATES DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY SMALL MOLECULE, 2018-2024 (USD MILLION)
TABLE 246. UNITED ARAB EMIRATES DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY SMALL MOLECULE, 2025-2030 (USD MILLION)
TABLE 247. UNITED ARAB EMIRATES DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 248. UNITED ARAB EMIRATES DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 249. UNITED ARAB EMIRATES DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 250. UNITED ARAB EMIRATES DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 251. UNITED ARAB EMIRATES DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 252. UNITED ARAB EMIRATES DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 253. SAUDI ARABIA DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 254. SAUDI ARABIA DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 255. SAUDI ARABIA DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY ANTISENSE OLIGONUCLEOTIDE, 2018-2024 (USD MILLION)
TABLE 256. SAUDI ARABIA DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY ANTISENSE OLIGONUCLEOTIDE, 2025-2030 (USD MILLION)
TABLE 257. SAUDI ARABIA DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY GENE THERAPY, 2018-2024 (USD MILLION)
TABLE 258. SAUDI ARABIA DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY GENE THERAPY, 2025-2030 (USD MILLION)
TABLE 259. SAUDI ARABIA DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY SMALL MOLECULE, 2018-2024 (USD MILLION)
TABLE 260. SAUDI ARABIA DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY SMALL MOLECULE, 2025-2030 (USD MILLION)
TABLE 261. SAUDI ARABIA DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 262. SAUDI ARABIA DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 263. SAUDI ARABIA DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 264. SAUDI ARABIA DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 265. SAUDI ARABIA DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 266. SAUDI ARABIA DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 267. SOUTH AFRICA DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 268. SOUTH AFRICA DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 269. SOUTH AFRICA DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY ANTISENSE OLIGONUCLEOTIDE, 2018-2024 (USD MILLION)
TABLE 270. SOUTH AFRICA DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY ANTISENSE OLIGONUCLEOTIDE, 2025-2030 (USD MILLION)
TABLE 271. SOUTH AFRICA DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY GENE THERAPY, 2018-2024 (USD MILLION)
TABLE 272. SOUTH AFRICA DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY GENE THERAPY, 2025-2030 (USD MILLION)
TABLE 273. SOUTH AFRICA DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY SMALL MOLECULE, 2018-2024 (USD MILLION)
TABLE 274. SOUTH AFRICA DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY SMALL MOLECULE, 2025-2030 (USD MILLION)
TABLE 275. SOUTH AFRICA DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 276. SOUTH AFRICA DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 277. SOUTH AFRICA DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 278. SOUTH AFRICA DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 279. SOUTH AFRICA DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 280. SOUTH AFRICA DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 281. DENMARK DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 282. DENMARK DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 283. DENMARK DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY ANTISENSE OLIGONUCLEOTIDE, 2018-2024 (USD MILLION)
TABLE 284. DENMARK DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY ANTISENSE OLIGONUCLEOTIDE, 2025-2030 (USD MILLION)
TABLE 285. DENMARK DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY GENE THERAPY, 2018-2024 (USD MILLION)
TABLE 286. DENMARK DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY GENE THERAPY, 2025-2030 (USD MILLION)
TABLE 287. DENMARK DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY SMALL MOLECULE, 2018-2024 (USD MILLION)
TABLE 288. DENMARK DRUGS FOR SPINAL MUSCULAR ATROPHY MARKET SIZE, BY SMALL MOLECULE, 2025-2030 (USD MILLION)
TABLE 289. DENMARK DRUGS FOR SPINAL MUSCULAR ATROPHY M

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Drugs for Spinal Muscular Atrophy market report include:
  • Astellas Pharma Inc.
  • Biogen Inc.
  • Novartis AG
  • PTC Therapeutics, Inc.
  • F. Hoffmann-La Roche Ltd.

Related Topics

Related Reports

Spinal Muscular Atrophy Treatment Market Report and Forecast 2025-2034 - Product Image

Spinal Muscular Atrophy Treatment Market Report and Forecast 2025-2034

  • Report
  • 400 Pages
  • Global
From
Spinal Muscular Atrophy Treatment Global Market Report 2025 - Product Image

Spinal Muscular Atrophy Treatment Global Market Report 2025

  • Report
  • 175 Pages
  • Global
From
Spinal Muscular Atrophy Treatment Market by Treatment Type (Gene Therapy, SMN2-Targeted Therapy, Supportive Therapy), Disease Type (Type 1, Type 2, Type 3), End User - Global Forecast 2025-2030 - Product Image

Spinal Muscular Atrophy Treatment Market by Treatment Type (Gene Therapy, SMN2-Targeted Therapy, Supportive Therapy), Disease Type (Type 1, Type 2, Type 3), End User - Global Forecast 2025-2030

  • Report
  • 184 Pages
  • Global
From
Spinal Muscular Atrophy Treatment Market Size, Share & Trends Analysis Report By Type, By Treatment, By Route of Administration, By Region, And Segment Forecasts, 2025 - 2030 - Product Image

Spinal Muscular Atrophy Treatment Market Size, Share & Trends Analysis Report By Type, By Treatment, By Route of Administration, By Region, And Segment Forecasts, 2025 - 2030

  • Report
  • 100 Pages
  • Global
From
Spinal Muscular Atrophy - Pipeline Insight, 2025 - Product Image

Spinal Muscular Atrophy - Pipeline Insight, 2025

  • Clinical Trials
  • 80 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.